Levobunolol. A three-month efficacy study in the treatment of glaucoma and ocular hypertension
R. E. Bensinger, E. U. Keates, J. D. Gofman, G. D. Novack and E. Duzman
The ocular hypotensive effect and the safety of levobunolol hydrochloride
(0.5% and 1%) were compared with vehicle in this double-masked study of 42
patients with chronic open-angle glaucoma or ocular hypertension. After a
washout of ocular hypotensive medication, patients received one of the
three test treatments in both eyes twice daily for three months. Both
concentrations of levobunolol produced significant reductions in
intraocular pressure, while decreases in vehicle-treated patients were
minimal. Over the three-month study period, average pressure reductions
were approximately 9.0 mm Hg in patients receiving either concentration of
levobunolol and 0.5 mm Hg in patients receiving vehicle. Fewer patients
were terminated from the study for inadequately controlled intraocular
pressure in the levobunolol groups than in the vehicle group. No patients
were terminated for drug-related adverse experiences.